Piper Jaffray Starts Neothetics Inc. (NEOT) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Needham & Company Starts Neothetics Inc. (NEOT) at Buy
December 15, 2014 6:41 AM ESTNeedham & Company initiates coverage on Neothetics Inc. (NASDAQ: NEOT) with a Buy rating and a price target of $17.00.
Analyst Elliot Wilbur commented, "We initiate coverage of Neothetics (NEOT), a clinical-stage specialty pharma company focused on developing and commercializing innovative and differentiated... More
Guggenheim Starts Neothetics Inc. (NEOT) at Buy
December 15, 2014 6:04 AM ESTGuggenheim initiates coverage on Neothetics Inc. (NASDAQ: NEOT) with a Buy rating and a price target of $16.00.
Analyst Louise Chen highlighted the company's two products in development:
LIPO-202 (Salmeterol Xinafoate for Injection): Injectable designed to produce local, selective fat tissue reduction (pharmaceutical lipoplasty).LIPO-102 (Salmeterol Xinafoate and Fluticasone Propionate): Orphan designation for treatment of... More